Sales & Support: 314-485-5210



Catalogue number:
50 mg
Product is available in:
  • USA
  • Canada
$50.00 Shipping is calculated in checkout

Thioredoxin reductase inhibitor, leading to unfolded protein response (UPR). Gold-containing drug that smothers infection of, and cytokine induction by, SARS-CoV-2 in cells. Rothan et al. bioRxiv, Apr 15 2020, https://doi.org/10.1101/2020.04.14.041228.

  • Datasheet:   view or download
  • Applications:Approved drug (U.S.) that could be repurposed
Product Type:

Biochemicals & reagents

CAS Number:



1) Columbo et al. (1990), Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin; Biochem. Pharmacol., 39 285. / 2) Rigobello et al. (2002), Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative; Br.J. Pharmacol., 136 1162 / 3) Merck 14 878

Limit of Detection:


Storage Temperature:

Room Temperature

Additional Information:

Auranofin is a disease-modifying antirheumatic drug (DMARD) which is a potent inhibitor of selenoenzyme thioredoxin reductase and IκB kinase (IKK) by modifying Cys-179. This compound is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions.